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ABSTRACT: 38 
Chronic pulmonary aspergillosis (CPA) is often poorly responsive to antifungal treatment; 39 
secondary infections increase morbidity/mortality, particularly in progressive cases.  40 
Interferon gamma (IFNγ) has been implicated in not only Aspergillus control but also 41 
bacterial clearance.  Clinical notes of patients with CPA treated with IFNγ (2011-2018) were 42 
retrospectively hand-searched.  In patients treated for >12 months (n=20), the frequency of 43 
acute exacerbation reduced from 3.1 to 1.4 episodes/year (p=0.006) in the 12 months after 44 
treatment initiation compared to the 12 months before.  A significant reduction in the 45 
frequency of hospital admissions/year was also observed (0.8 to 0.3, p=0.04).  These findings 46 
support further prospective studies. 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
MAIN TEXT: 72 
 73 
Background: 74 
Chronic pulmonary aspergillosis (CPA) is characterised by persistent Aspergillus infection, 75 
usually complicating pre-existing lung disease such as COPD or bronchiectasis.  Although 76 
patients are typically without immunocompromise, impaired interferon gamma (IFNγ) and/or 77 
interleukin 12 (IL-12) production have been reported.
1
  IFNγ prevents conidial germination, 78 
enhances alveolar macrophage killing capacity and manipulates Th1 CD4 cell/NK cell influx 79 
through chemokine signalling.
2-4
  As such, IFNγ supplementation has been explored as a 80 
salvage therapy for severe CPA in patients with impaired IFNγ production.5,6  IFNγ 81 
immunotherapy may have additional benefits as CPA is often complicated by recurrent 82 
bacterial superinfection; in chronic granulomatous disease, therapeutic IFNγ reduces bacterial 83 
infections by up to 70%.
7
 84 
 85 
This study reports the impact of subcutaneous IFNγ supplementation on the frequency of 86 
acute exacerbation and all-cause hospital admission when administered as salvage therapy to 87 
patients with severe CPA, refractory to antifungals, and proven impairment of IFNγ 88 
production. 89 
 90 
Methods: 91 
For this descriptive study, clinic letters and electronic hospital records were retrospectively 92 
hand-searched for all patients prescribed IFNγ salvage therapy for CPA at the National 93 
Aspergillosis Centre, Manchester, UK between January 2011 and September 2018 (46 94 
patients).  Subcutaneous IFNγ was self-administered at a dose of 50µg three times weekly 95 
and prescribed according to clinical judgement when antifungal therapy appeared to be 96 
failing due to a combination of clinical, microbiological and radiological parameters in 97 
patients with impaired production of IFNγ or IL-12 after in vitro cytokine induction.   98 
 99 
For the induction of IFNγ, whole blood samples from patients and healthy controls were 100 
diluted 1:5 (Roswell Park Memorial Institute medium) into 96 well F plates (Corning) and 101 
activated with lipopolysaccharide (List Biochemicals, 1µg/ml) or phytohemagglutinin 102 
(Sigma, 10µg/ml), alone or in co-stimulation with IL-12 (Immunotools, 5µg/ml), and 103 
incubated at 37°C/5% CO2.  For the induction of IL-12, whole blood was stimulated as above 104 
with lipopolysaccharide, alone or in combination with IFNγ (Immukin, Boehringer, 2x104 105 
IU/ml).  Supernatants were taken after 24 hours and cytokine levels measured by standard 106 
ELISA (IFNγ: Pelikine, Sanquin, NL) or multiplexed particle-based flow cytometry (IL-12: 107 
R+D Systems Fluorokinemap), according to the manufacturer’s recommendations. 108 
 109 
Patients were excluded from analysis if they started IFNγ therapy within 12 months of the 110 
patient search (n=5), were lost to follow-up (n=4) or started IFNγ prior to attending clinic 111 
(n=1).  The frequency of exacerbation, defined as an acute respiratory decline clinically 112 
requiring a course of antibiotics, and all-cause hospital admission were compared between 113 
the 12 months pre-/post- IFNγ initiation, stratified by duration of IFNγ therapy (Wilcoxon 114 
matched-pairs signed-rank test).  Incidence rates of death were compared on/off IFNγ for the 115 
36 patients meeting inclusion criteria, starting from the day of IFNγ initiation through to 116 
September 2018 for a maximum follow-up of 60 months. 117 
 118 
Results: 119 
Of the 36 patients meeting the inclusion criteria, 20 received IFNγ for >12 months, eight 120 
stopped treatment due to side effects (all receiving IFNγ for <6 months, mean duration 2.5 121 
months) and eight patients died within 12 months of initiating treatment (mean IFNγ duration 122 
4.6 months, mean survival 7.5 months).  Demographic characteristics of these 36 patients are 123 
shown in Table 1.   124 
 125 
Death rate was statistically similar whilst receiving IFNγ therapy (0.16/year) compared to 126 
after stopping IFNγ (0.12/year) (p=0.6), with a median follow-up of 33.5 months 127 
(interquartile range 13-45 months).  The 28 patients alive at 12 months were included in 128 
further analysis.  129 
 130 
Twenty-two patients (79%) were on concomitant antifungal therapy and eight (29%) were  131 
taking azithromycin long-term whilst receiving IFNγ.  Two patients stopped antifungals as 132 
they transitioned to IFNγ and azithromycin was started and stopped for one/two  133 
patients respectively in the 12 months preceding IFNγ initiation.  All remaining patients  134 
had the same on/off antifungal and azithromycin status throughout the 24 months of 135 
comparison (12 months pre-/post- IFNγ initiation), though most patients on antifungals 136 
changed their regimen at some point due to adverse effects, azole resistance and/or clinical 137 
failure (Figure 1). 138 
 139 
In patients treated for >12 months (n=20), there was a significantly lower number of acute 140 
exacerbations and hospital admissions in the year following IFNγ initiation compared to the 141 
year prior (Table 2).  No significant changes were seen in patients treated with IFNγ for <6 142 
months for both outcomes (n=8).  Patients receiving IFNγ for >12 months (versus <6 months) 143 
were observed to have a greater difference between pre-/post- IFNγ initiation frequencies of 144 
acute exacerbation and hospital admission, although not significantly so for exacerbation.  145 
Figure 1 demonstrates the number of acute exacerbations and hospital admissions in the 12 146 
months pre-/post- IFNγ therapy initiation on an individual basis.   147 
 148 
Of the 10 patients that remained on the same antifungal treatment throughout the 24 month 149 
observation period, eight received IFNγ for >12 months (negative outcomes 150 
lower/equal/higher in 6/1/1 patients) and two received IFNγ for <6 months (negative 151 
outcomes lower/equal/higher in 0/1/1 patients). 152 
 153 
Discussion: 154 
In this retrospective, descriptive study, patients with CPA refractory to antifungals alone 155 
appeared to have lower frequencies of acute exacerbation and all-cause hospital admission 156 
after the introduction of IFNγ therapy.  These effects were observed when IFNγ was given 157 
for >12 months, but not for durations <6 months.  Our observation is promising as acute 158 
exacerbations and hospital admissions are a substantial cause of morbidity and mortality in 159 
this patient population.  160 
 161 
Almost all patients in our study had impaired IFNγ production and those that did not had 162 
reduced levels of IL-12, a cytokine that stimulates IFNγ production.  It is not clear if this 163 
represents a primary immune defect or a consequence of chronic pulmonary disease or 164 
infection.  The apparent beneficial effect of IFNγ suggests this is clinically relevant and could 165 
be mediated by its antibacterial, antiviral or antifungal action.  Due to the chronicity of CPA 166 
and the number of patients treated, it was not possible to document a meaningful effect of 167 
IFNγ on CPA’s clinical course; there was no significant effect on Aspergillus serology, extent 168 
of CPA on imaging, microbiological eradication of Aspergillus or significant change in 169 
profile of possible pathogenic organisms from sputum culture (data not shown).  The 170 
frequency of adverse events and treatment discontinuation was high in this population of 171 
severely ill patients.  172 
 173 
Long-term antifungals are the treatment of choice for CPA; most of our patients were on 174 
azoles.  In addition, long-term macrolide treatment is often used for its anti-inflammatory 175 
properties and to prevent bacterial exacerbations in patients with chronic lung disease; 176 
several of our patients were taking azithromycin during the observation period.
8,9
  177 
Admittedly, the concomitant use of antifungal and antibacterial treatment, with changes in 178 
regimen occurring in the majority of patients during the 24 month observation, may confound 179 
the results of this study.  Only a minority of patients, however,  had changes in their overall 180 
on/off treatment status during this time. 181 
 182 
The patients included in this study were highly heterogeneous and treatment was  183 
individualised.  Given this heterogeneity, using patients as their own comparator was 184 
considered to be the fairest way to present this retrospective data but is not without its flaws.  185 
Having failed to respond to antifungal therapy they had poor prognosis from the offset.  186 
There is potential for introduction for bias if patients with a poorer physiological reserve 187 
responded less favourably to IFNγ therapy, self-selecting into the <6 month treatment group.  188 
Patients lost to follow-up may also introduce further bias. 189 
 190 
Patients that died within 12 months of therapy initiation were not included in the final 191 
analysis, arguably introducing bias by excluding the most physiologically vulnerable or 192 
patients with the most severe CPA.  It is important to note, however, that all patients had 193 
declining prognostic indicators prior to starting IFNγ.  Inclusion of patients that died during 194 
the study period would itself have introduced its own bias; the methodology of a self-195 
controlled case series was considered but deemed inappropriate due to death being a common 196 
outcome and the number of patients available.
10
  There was no evidence of IFNγ therapy 197 
being detrimental to health; side effects leading to withdrawal were all mild and there was no 198 
difference in death rates between patients on/off IFNγ.  199 
 200 
In summary, the frequency of acute exacerbation and hospital admission were lower after the 201 
introduction of IFNγ replacement therapy in patients with severe, refractory CPA.  202 
Prospective data are needed to further evaluate the role of IFNγ as adjunctive therapy.  In 203 
addition to control of fungal burden, IFNγ may improve CPA morbidity/mortality by 204 
reducing the frequency and severity of bacterial or viral superinfection.  These findings could 205 
apply to patients with other chronic lung diseases. 206 
 207 
Table 1.  Baseline characteristics of participants at INFγ testing 
Characteristic 
Total (n = 36) 
n (%) 
Age group, years 
   
 
<40 
  
3 (8) 
 
40-49 
  
1 (3) 
 
50-59 
  
19 (53) 
 
60-69 
  
10 (28) 
 
≥70 
  
3 (8) 
 
Age, years, median [IQR] 
 
56 [51 - 65.5]* 
Female sex 
  
18 (50)* 
Smoking status 
   
 
Active 
  
8 (22) 
 
Ex-smoker 
  
9 (25) 
 
Never 
  
19 (53) 
Underlying pulmonary comorbidity† 
 
 
ABPA 
  
5 (14) 
 
Asthma 
  
6 (17) 
 
Bronchiectasis 
 
13 (36) 
 
COPD 
  
8 (22) 
 
Fibrosis (secondary to connective tissue disease) 5 (14) 
 
Malignancy 
  
2 (6) 
 
NTM infection (active/previously treated) 6 (17) 
 
Non-COPD bullous lung disease 3 (8) 
 
Pneumothorax (previous) 
 
6 (17) 
 
Sarcoidosis 
  
2 (6) 
 
TB (previously treated) 
 
5 (14) 
IFNγ = interferon gamma, IQR = interquartile range, ABPA = allergic bronchopulmonary aspergillosis, COPD = 
chronic obstructive pulmonary disease, NTM = non-tuberculous mycobacterium, TB = tuberculosis 
*Demographics stratified by 12 month survival/exclusion:  
Alive (n = 28), median age 56.5 [IQR 50.5-65] years, sex 13/28 (46%) female  
Dead (n = 8), median age 55.5 [53-75 IQR] years, sex 5/8 (63%) female  
†Not mutually exclusive: patients could have more than one underlying pulmonary comorbidity 
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 218 
Table 2.  Number of acute exacerbations and hospital admissions pre-/post- IFNγ initiation 
Outcome and population 
Mean events over 12 months 
(standard deviation) P value 
Pre- IFNγ initiation Post- IFNγ initiation 
Acute exacerbations (clinically requiring antibiotics)a 
   
 
IFNγ duration 
   
  
>12 months (n = 20) 3.1 (2.4) 1.4 (1.5) 0.006 
  
<6 months (n = 8) 2.8 (1.8) 2.6 (1.8) 0.7 
Hospital admissionsa 
   
 
IFNγ duration 
   
  
>12 months (n = 20) 0.8 (0.9) 0.3 (0.6) 0.04 
  
<6 months (n = 8) 0.6 (0.7) 1.0 (1.1) 0.5 
Comparison between >12 and <6 month IFNγ durationb 
  
 
Acute exacerbations - - 0.06 
  Hospital Admission - - 0.02 
a Wilcoxon matched-pairs signed rank test, b t-test 
IFNγ = interferon gamma 
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Figure legend: 341 
Figure 1.   342 
Individual and mean frequencies of acute exacerbation and hospital admission in the 12 343 
months pre-/post- IFNγ initiation, with illustration of concomitant antifungal/azithromycin 344 
treatment regimen, stratified by IFNγ treatment duration.  SD = standard deviation.  345 
